Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Thromboplastin sensitivity to clotting factors can be modulated
September 20th, 2006
Recent research from the United States has documented that traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. "Thromboplastin reagents are used to conduct prothrombin time (PT) clotting tests to monitor oral anticoagulant therapy and screen for clotting factor deficiencies. Thromboplastins made from purified, recombinant tissue factor are generally more sensitive to changes in plasma factor (F) VII levels than are thromboplastins prepared from tissue extracts." "This may be problematic as FVII's short plasma half-life can result in day-to-day fluctuation during oral anticoagulant therapy. We hypothesized...
Source: Biotech Week (2006-09-20)
|
